quil-a has been researched along with Taeniasis* in 2 studies
2 other study(ies) available for quil-a and Taeniasis
Article | Year |
---|---|
Elimination of Taenia solium transmission to pigs in a field trial of the TSOL18 vaccine in Cameroon.
A pilot field trial of the TSOL18 vaccine was undertaken in Cameroon. Two hundred and forty, 2-3 month-old piglets were distributed to 114 individual households in pairs. Vaccinated animals received three immunisations with 200 microg TSOL18 plus 5 mg Quil A and 30 mg/kg oxfendazole at the time of the second immunisation. Necropsies were undertaken when the pigs were approximately 12 months of age. Viable Taenia solium cysticerci were identified in 20 control pigs (prevalence 19.6%); no cysticerci were found in any of the vaccinated animals (P<0.0001). Combined application of TSOL18 vaccination and a single oxfendazole treatment in pigs may be a relatively simple and sustainable procedure that has the potential to control T. solium transmission in endemic areas and, indirectly, reduce the number of new cases of neurocysticercosis in humans. Topics: Adjuvants, Immunologic; Animals; Anthelmintics; Antigens, Helminth; Benzimidazoles; Cameroon; Immunization, Secondary; Quillaja Saponins; Saponins; Swine; Swine Diseases; Taenia solium; Taeniasis; Vaccines; Vaccines, Subunit | 2010 |
Sequential nucleic acid and recombinant adenovirus vaccination induces host-protective immune responses against Taenia ovis infection in sheep.
Sheep were immunized with a protective recombinant antigen (45W) from the cestode parasite Taenia ovis using three different vaccine delivery systems, either alone or in different combinations. The DNA encoding 45W was cloned into the expression plasmid pcDNA 3 and an ovine adenovirus to create nucleic acid and recombinant viral vector vaccines, respectively. Sheep received two vaccinations with various combinations of these two delivery systems and/or purified recombinant 45W protein in a conventional vaccine formulation containing Quil A as adjuvant (protein/Quil A vaccine). Sheep receiving two inoculations of either the nucleic acid or the recombinant adenovirus alone, demonstrated only low levels of 45W-specific antibody. However, immunization with either nucleic acid or recombinant adenovirus primed animals to mount an enhanced immune response after a subsequent vaccination with the protein/ Quil A vaccine. The most striking result was that sheep initially immunized with the nucleic acid vaccine and boosted with the recombinant adenovirus, mounted IgG1 responses > 65 fold higher than those of sheep receiving either vaccine alone. The level of antibody in these sheep was commensurate with that observed in animals vaccinated twice with the protein/Quil A adjuvanted vaccine. In both cases, host-protection from experimental challenge infection with T. ovis was obtained. Topics: Adenoviridae; Adjuvants, Immunologic; Animals; Antibodies, Helminth; Antigens, Helminth; DNA, Helminth; Female; Genetic Vectors; Male; Quillaja Saponins; Saponins; Sheep; Sheep Diseases; Taeniasis; Vaccination; Vaccines, DNA; Vaccines, Synthetic | 1997 |